Holoclar
Holoclar is a stem cell therapy for people with severe limbal stem cell deficiency due to burns in the eye.[1][2]
Its approval in 2015 by the European Commission was the first time that a stem cell therapy, other than the use of umbilical cord stem cells, was allowed to be sold by any regulatory agency in the world.[3]
It works by seeding stem cells to promote the regrowth of the cornea.[3][4]
Manufacturing and logistics
Once cultured at the lab in Germany the cells must be implanted within 36 hours.[5]
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (February 2016) |
See also
References
- ^ European Medicines Agency. "First stem-cell therapy recommended for approval in EU". Retrieved 3 March 2015.
- ^ Knapton, Sarah (19 December 2014). "First stem-cell therapy approved for medical use in Europe". The Telegraph. Retrieved 3 March 2015.
- ^ a b Abbott, Alison (3 March 2015). "Behind the scenes of the world's first commercial stem-cell therapy". Nature News. Retrieved 3 March 2015.
- ^ Pellegrini G, Rama P, Di Rocco A, Panaras A, De Luca M (2014). "Concise review: hurdles in a successful example of limbal stem cell-based regenerative medicine". Stem Cells. 32 (1): 26–34. doi:10.1002/stem.1517. PMID 24038592.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Short shelf-life poses problems for cell therapy makers, Chiesi
| Sources/types | |
|---|---|
| Cell potency |
|
| Related articles | |
